Published in
American Association for the Advancement of Science, Science Translational Medicine, 465(10), 2018
DOI: 10.1126/scitranslmed.aah4066
Links
Tools
Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice
Journal article published in 2018 by
Richard Gordon 
,
Eduardo A. Albornoz ,
Daniel C. Christie ,
Monica R. Langley ,
Vinod Kumar ,
Susanna Mantovani ,
Avril A. B. Robertson ,
Mark S. Butler ,
Dominic B. Rowe ,
Luke A. O’Neill,
Anumantha G. Kanthasamy ,
Kate Schroder ,
Matthew A. Cooper ,
Trent M. Woodruff
,
Eduardo A. Albornoz ,
Daniel C. Christie ,
Monica R. Langley ,
Vinod Kumar ,
Susanna Mantovani ,
Avril A. B. Robertson ,
Mark S. Butler ,
Dominic B. Rowe ,
Luke A. O’Neill,
Anumantha G. Kanthasamy ,
Kate Schroder ,
Matthew A. Cooper ,
Trent M. Woodruff
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
Oral treatment with a brain-penetrant NLRP3 inhibitor has protective effects in preclinical models of Parkinson’s disease.